GRI Bio (GRI) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing therapies for diseases with dysregulated immune responses, focusing on inflammatory, fibrotic, and autoimmune disorders.

• Lead candidate GRI-0621 is an oral iNKT cell inhibitor targeting severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis (IPF).

• Pipeline includes GRI-0803, an oral agonist for autoimmune disorders, and a proprietary library of 500+ compounds.

• Plans to advance GRI-0621 to Phase 2b trials and GRI-0803 to IND-enabling studies and Phase 1 trials, pending additional funding.

Financial performance and metrics

• As of January 26, 2026, 525,358 shares of common stock outstanding, held by 13 stockholders of record.

• Financial statements for years ended December 31, 2024 and 2023 audited with an emphasis on ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital and administrative expenses.

• Management has broad discretion in allocating proceeds; funds may be invested in interest-bearing, investment-grade securities until used.